An investigation of the monoamine oxidase inhibition properties of benzothiazole derivatives

IF 2.5 Q2 CHEMISTRY, MULTIDISCIPLINARY Results in Chemistry Pub Date : 2025-03-01 DOI:10.1016/j.rechem.2025.102142

Anandie le Roux , Anél Petzer , Stephanus J. Cloete , Jacobus P. Petzer

{"title":"An investigation of the monoamine oxidase inhibition properties of benzothiazole derivatives","authors":"Anandie le Roux , Anél Petzer , Stephanus J. Cloete , Jacobus P. Petzer","doi":"10.1016/j.rechem.2025.102142","DOIUrl":null,"url":null,"abstract":"<div><div>Literature reports that alkyloxy substituted coumarin derivatives inhibit the monoamine oxidase (MAO) enzymes, specifically the MAO-B isoform. To further investigate this finding, the present study synthesised and evaluated a series of alkyloxy substituted benzothiazole derivatives as potential inhibitors of human MAO-A and MAO-B. The results showed that 6-((4-nitrobenzyl)oxy)benzo[<em>d</em>]thiazole (<strong>1f</strong>) was the most potent MAO-A inhibitor with an IC<sub>50</sub> value of 0.336 μM, while the most potent MAO-B inhibitors were 6-((3-chlorobenzyl)oxy)benzo[<em>d</em>]thiazole (<strong>1e</strong>) and 4-((benzo[<em>d</em>]thiazol-6-yloxy)methyl)benzonitrile (<strong>1i</strong>), which both demonstrated IC<sub>50</sub> values of 0.0028 μM. For comparison, the reference MAO-A and MAO-B inhibitors, toloxatone and safinamide, exhibited IC<sub>50</sub> values of 1.67 and 0.240 μM, respectively. Potential binding modes and interactions of the inhibitors with MAO were proposed with molecular docking. This study concluded that the benzothiazole derivatives were potent and specific MAO-B inhibitors. Inhibitors of MAO-A are used to treat neuropsychiatric disorders (e.g., depression and anxiety disorder), while MAO-B inhibitors are established therapy for Parkinson's disease.</div></div>","PeriodicalId":420,"journal":{"name":"Results in Chemistry","volume":"14 ","pages":"Article 102142"},"PeriodicalIF":2.5000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Results in Chemistry","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2211715625001250","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Literature reports that alkyloxy substituted coumarin derivatives inhibit the monoamine oxidase (MAO) enzymes, specifically the MAO-B isoform. To further investigate this finding, the present study synthesised and evaluated a series of alkyloxy substituted benzothiazole derivatives as potential inhibitors of human MAO-A and MAO-B. The results showed that 6-((4-nitrobenzyl)oxy)benzo[d]thiazole (1f) was the most potent MAO-A inhibitor with an IC₅₀ value of 0.336 μM, while the most potent MAO-B inhibitors were 6-((3-chlorobenzyl)oxy)benzo[d]thiazole (1e) and 4-((benzo[d]thiazol-6-yloxy)methyl)benzonitrile (1i), which both demonstrated IC₅₀ values of 0.0028 μM. For comparison, the reference MAO-A and MAO-B inhibitors, toloxatone and safinamide, exhibited IC₅₀ values of 1.67 and 0.240 μM, respectively. Potential binding modes and interactions of the inhibitors with MAO were proposed with molecular docking. This study concluded that the benzothiazole derivatives were potent and specific MAO-B inhibitors. Inhibitors of MAO-A are used to treat neuropsychiatric disorders (e.g., depression and anxiety disorder), while MAO-B inhibitors are established therapy for Parkinson's disease.

Abstract Image